Presents advances in knowledge of the main urological cancers, from a multidisciplinary perspective. It opens with an overview of controversial issues in the diagnosis and treatment of prostate cancer, followed by a paper on animal models and preliminary experience with oral biopriminine in phase I-II trials. The next four presentations focus on superficial bladder cancer and include an overview of recent literature and results from ongoing clinical trials. Further contributions demonstrate the importance of randomized clinical trials to the care of patients with bladder cancer and provide a review of the diagnosis and treatment of kidney cancer. The final chapters deal with quality of life, statistical design of trials and health economics.
